The purpose of the study is to describe the safety profile of the PG4 vaccine. Infants receive a single dose of either the study vaccine or the comparison vaccine and are then observed for a short time after the injection, followed by scheduled visits to check their health over the next weeks.

Researchers will watch for common side effects such as redness, swelling, pain at the injection site, fever, reduced appetite, irritability, or increased sleep. Any side effects, known as adverse events, and any serious side effects that require medical attention, called serious adverse events, will be recorded and reviewed.

The study involves healthy participants aged 16 to 40 years. Participants will receive the mRNA-1647 vaccine or a placebo through a series of three injections. The trial will monitor participants over a period of time to see if the vaccine can prevent CMV infection and to check for any side effects. The study will also involve the use of Sodium Chloride 0.9%, which is a common solution used in medical settings, as part of the injection process.

The main goal of the study is to demonstrate the effectiveness of the mRNA-1647 vaccine in preventing CMV infection in participants who have not been previously exposed to the virus. The trial will also assess the safety of the vaccine and how well it is tolerated by participants. This research is important for developing new ways to protect people from CMV and improve public health outcomes.

The purpose of this study is to learn about the safety of the GBS vaccine in pregnant women and their babies, and to measure how well the vaccine helps the mother’s body create protective substances called antibodies that can be passed to the baby. These antibodies are measured to see if they could protect infants from GBS infections that can occur in the first days after birth, called early-onset disease, or infections that happen later in the first months of life, called late-onset disease. The study will look at whether the vaccine can create enough antibodies against all six types of GBS bacteria included in the vaccine.

During the study, pregnant women between 24 and 36 weeks of pregnancy will receive either the vaccine or placebo. The study will monitor the pregnant women for any reactions at the injection site such as redness, swelling, or pain, as well as general symptoms like fever, nausea, vomiting, diarrhea, headache, tiredness, muscle pain, and joint pain. Blood samples will be taken from mothers and their babies at different times to measure antibody levels. The babies will be followed after birth to check their health and safety, and to measure the antibodies they received from their mothers through the vaccine.

The vaccine is given as a suspension for intramuscular injection using a pre-filled syringe. Each participant will receive one dose of 0.5 milliliters of the vaccine. The study compares the immune response between people who received the vaccine in early childhood and those who have never received it before.

The main purpose is to determine if people previously vaccinated with Bexsero show a stronger immune response to a booster dose compared to those receiving the vaccine for the first time. The study will monitor participants for 31 days after vaccination to assess both the immune response and safety of the vaccine.

The purpose of the study is to determine if the new high-dose vaccine is at least as effective as the existing vaccine in producing an immune response. Participants will receive either the new vaccine or the existing one through an injection. The study will monitor the immune response by measuring specific antibodies in the blood 28 days after vaccination. Participants will also be observed for any side effects or adverse reactions following the vaccination.

The study will take place over several months, with participants being followed up to six months after receiving the vaccine. This will help researchers gather comprehensive data on the vaccine’s safety and its ability to trigger a strong immune response. The ultimate goal is to ensure that the new high-dose vaccine provides effective protection against influenza in older adults, who are at higher risk for complications from the flu.

The purpose of the study is to evaluate how well this vaccine works in preventing RSV infections in infants and toddlers. Participants in the study will receive two doses of the vaccine. The study will observe the effects of the vaccine over the course of the RSV season, which is the time of year when RSV infections are most common. The study will also include a group that receives a placebo to compare the results.

Throughout the study, researchers will monitor the health of the participants to ensure their safety and to gather information on how the vaccine affects the immune system. The study aims to provide valuable insights into the vaccine’s ability to prevent RSV-related illnesses, such as lower respiratory tract disease, which affects the lungs and can lead to more serious health issues. The study is expected to continue until 2026, with recruitment starting in 2024.

The purpose of the study is to evaluate how well the MenQuadfi vaccine works and how safe it is when given as a booster dose to children and adolescents. These participants had previously received the vaccine as toddlers. The study will look at how the immune system responds to the booster dose and how long the protection lasts. Participants will receive the vaccine through an injection into the muscle, and the study will monitor their immune response over time.

Throughout the study, researchers will collect information on the participants’ immune responses to the vaccine and any side effects they may experience. This will help determine the effectiveness of the booster dose in maintaining protection against meningococcal infection. The study aims to provide valuable insights into the long-term benefits of the MenQuadfi vaccine in preventing serious bacterial infections in children and adolescents.

The purpose of the study is to evaluate how well the vaccine works in generating an immune response, its safety, and how it affects the occurrence of RSV-related respiratory illnesses in adults aged 60 years and older. Participants in the study will receive a single dose of the vaccine, and their immune response will be monitored over time. The study will compare the immune responses of participants from different regions to ensure the vaccine is effective across diverse populations.

Throughout the study, participants will be observed for any side effects or reactions to the vaccine. The study will also track the occurrence of any respiratory illnesses related to RSV. Some participants will receive a placebo for comparison. The study aims to provide valuable information on the vaccine’s effectiveness and safety in preventing RSV infections in older adults.

Participants in the study will receive either the new *PCV21* vaccine or the *Vaxneuvance* vaccine. The vaccines are given as a series of injections into the muscle. The study will monitor the immune response by measuring the levels of antibodies, which are proteins the body makes to fight infections. The study will also check for any side effects or reactions to the vaccines. The goal is to ensure that the new vaccine is safe and effective for young children.

The study will last for several months, with follow-up visits to check the health and immune response of the participants. The researchers will look at how well the vaccines work against the different types of pneumococcal bacteria included in the vaccines. This information will help determine if the new vaccine can provide better protection against pneumococcal disease in children. The study will also track any immediate or long-term side effects to ensure the safety of the vaccines.

The purpose of the study is to evaluate how well the VLA15 vaccine works in preventing Lyme disease, as well as to assess its safety and how well it is tolerated by participants. The study will also look at the immune response generated by the vaccine, which is the body’s way of defending itself against infections. Participants in the study will receive a series of injections over a period of time and will be monitored for any reactions or side effects. The study will include people aged 5 years and older who live in areas where Lyme disease is common.

Throughout the study, participants will have regular check-ups to monitor their health and any potential side effects from the vaccine. The study aims to ensure that the vaccine is safe and effective for people of different ages, including children and adults. By participating in this study, researchers hope to gather important information that could lead to a new way to prevent Lyme disease in the future.

The purpose of the study is to evaluate how safe and well-tolerated Clesrovimab is compared to Palivizumab during the RSV season. Participants in the study will receive either Clesrovimab, Palivizumab, or a placebo. The study will monitor participants for any side effects, such as reactions at the injection site, fever, or other symptoms. The study will also look at how well the treatments work in preventing RSV-related illnesses that require medical attention or hospitalization.

Participants will be followed through two RSV seasons to gather information on the safety and effectiveness of the treatments. The study aims to provide valuable insights into how these treatments can help protect infants and children from severe RSV disease. The trial will help determine if Clesrovimab is a safe and effective option for preventing RSV infections in this vulnerable population.

The purpose of this study is to assess how well the Shingrix vaccine works over a long period, how safe it is, and how long the immune response lasts in older adults. Participants in the study will receive one or two additional doses of the vaccine. The study will follow participants for several years to monitor their health and the effectiveness of the vaccine in preventing shingles.

Throughout the study, participants will have regular check-ups to track their immune response and any side effects. The study will also look at the number of confirmed cases of shingles among participants and measure specific immune cells and antibodies that help protect against the virus. This information will help determine the long-term benefits and safety of the Shingrix vaccine for preventing shingles in older adults.

The purpose of the study is to observe how the children’s bodies react to the new vaccine. This includes monitoring for any local reactions like redness, swelling, or pain at the injection site, as well as systemic events such as fever, decreased appetite, increased sleepiness, or irritability. The study will also track any adverse events, which are unexpected medical problems that occur during the study, and serious adverse events, which are more severe health issues.

Additionally, the study will measure the levels of Immunoglobulin G (IgG), a type of antibody, and the opsonophagocytic activity (OPA), which is a measure of the vaccine’s ability to help the immune system fight off the bacteria. The trial is expected to provide valuable information on the vaccine’s safety and effectiveness in boosting the immune response in young children.

Participants in the study will receive two doses of either the MenQuadfi vaccine or the Nimenrix vaccine. The first dose will be administered when the infants are between 6 and 7 months old, and the second dose will be given when they are between 12 and 13 months old. The study will monitor the levels of antibodies, which are proteins in the blood that help fight infections, to see how well the vaccines work. The study will also track any side effects or reactions to the vaccines to ensure they are safe for use in young children.

The trial aims to demonstrate that the MenQuadfi vaccine is not less effective than the Nimenrix vaccine in producing an immune response. This will be measured by looking at the levels of antibodies in the blood after vaccination. The study will also observe any immediate or delayed reactions to the vaccines, including any serious adverse events. The results of this study will help determine the best vaccination strategy for protecting young children against meningococcal infection.

The purpose of the study is to see how well the IVX-A12 vaccine works in preventing lung infections caused by RSV and hMPV in adults aged 60 and older. Participants in the study will receive either the IVX-A12 vaccine or a placebo, which is a substance that looks like the vaccine but does not contain the active ingredients. The study will monitor participants over a period of time to check for any signs of these infections and to assess the safety of the vaccine.

Participants will be followed through different seasons to observe the occurrence of infections. The study aims to gather information on how effective the vaccine is in preventing these infections and to ensure it is safe for use in older adults. This research is important for developing new ways to protect against these common respiratory viruses.

Participants in the study will receive a single dose of the OVX836 vaccine through an injection. The study will monitor the occurrence of flu symptoms and any side effects after vaccination. The goal is to determine if the vaccine can effectively prevent the flu and to assess its safety. The study will also look at the body’s immune response to the vaccine, which involves measuring specific immune cells and antibodies that help fight the flu virus.

The trial will take place over a period of time, with participants being observed for any flu symptoms or side effects. The study will also evaluate the severity and duration of any flu-like symptoms that occur. By comparing the results between those who receive the OVX836 vaccine and those who receive a placebo, researchers aim to gather important information about the vaccine’s potential to protect against the flu.

The purpose of the study is to assess how well MK-1654 can prevent RSV-associated medically attended lower respiratory infections in both pre-term and full-term infants. The study will involve monitoring the infants from the time they receive the treatment up to 150 days afterward. During this period, researchers will observe the infants for any signs of RSV-related infections and any side effects that may occur.

Participants in the study will include healthy infants who are either early or moderate pre-term (born between 29 to 34 weeks and 6 days of gestational age) or late pre-term or full-term (born at 35 weeks or later). The study will also track any adverse events, such as fever or rash, to ensure the safety of the treatment. The ultimate goal is to determine if MK-1654 can effectively reduce the incidence of RSV-related infections in infants, providing a potential new option for preventing this common and sometimes serious virus.

The purpose of the study is to assess the clinical behavior of metastatic colorectal cancer and determine the overall possibility of surgically removing the cancer, as well as to observe any complications after surgery and the outcomes for patients. Participants in the study will receive either Fluorouracil or Capecitabine as part of their treatment plan. The study will monitor the patients over a period to gather information on how well the treatments work and the overall health and recovery of the patients.

This research is important for improving the understanding of metastatic colorectal cancer and finding better ways to treat it. By studying the effects of these medications and the potential for surgery, the study aims to provide valuable insights that could lead to improved treatment strategies and outcomes for patients with this type of cancer.

During the study, participants will receive either the new mRNA-1010 vaccine or a standard licensed influenza vaccine called Influsplit Tetra through an intramuscular injection. Both vaccines are designed to protect against different strains of influenza viruses. The study will monitor participants for any side effects and track how well the vaccines prevent flu-like illness caused by influenza viruses.

The research team will collect information about vaccine reactions in the first week after vaccination, track any unexpected health issues for 28 days, and continue monitoring participants’ health for approximately 6 months. They will also measure how well the body’s immune system responds to the vaccines by checking blood samples and documenting any cases of flu-like illness that occur during the study period.

The purpose of the study is to evaluate how safe and well-tolerated the new vaccine is, as well as how well it works in producing an immune response. Participants in the study will receive either the new vaccine, V116, or the existing vaccine, Pneumovax® 23, or a placebo. The study will monitor participants for any side effects and measure their immune response to the vaccine. This will help determine if the new vaccine is as effective or more effective than the existing one.

Participants will be followed for a period of time to observe any reactions to the vaccine and to measure the levels of antibodies, which are proteins in the blood that help fight infections. The study aims to provide valuable information on the potential benefits of the new vaccine for those at higher risk of pneumococcal disease, such as individuals with conditions like diabetes, chronic lung disease, or chronic heart disease. The results of this study could lead to improved prevention strategies for pneumococcal disease in vulnerable populations.

During the study, children will receive either the prednisolone sodium phosphate or a placebo, which is a substance with no active medication. The study will last for a short period, and the children will be monitored to see how quickly they recover from wheezing and if they need to stay in the hospital for a shorter time. The goal is to see if the medication helps them get better faster and reduces the need for additional medical care.

Parents and caregivers will be informed about the progress and any changes in the child’s condition throughout the study. The study will also track if the children experience any recurrence of wheezing or other related symptoms over a period of time after the initial treatment. This research is important to find better ways to help young children who suffer from wheezing due to viral infections.

The purpose of the study is to understand how well the vaccine works in creating an immune response, how safe it is, and how long its effects last. Participants in the study will receive a single dose of the vaccine and will be monitored over time to see how their bodies respond. The study will look at the immune response at different times, such as 30 days after the vaccination and then several months later, to see how the vaccine’s effects persist over time.

Participants will be adults aged 60 years and above. The study will involve regular check-ups and follow-ups to ensure the safety and effectiveness of the vaccine. The trial will also explore different schedules for giving additional doses of the vaccine to see if this improves the immune response. The study aims to provide valuable information on how this vaccine can help protect older adults from RSV infections.

Participants in the study will be randomly assigned to receive either Selatogrel or a Selatogrel matching placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will follow participants over a period to observe the occurrence of death or another heart attack after they have self-administered the treatment.

The study will also monitor for any safety concerns, such as bleeding events, that may occur within two days after taking the treatment. Additionally, researchers will look at other outcomes like hospital visits for heart failure within 30 days after treatment. This trial aims to provide valuable information on the potential benefits and risks of using Selatogrel for individuals at risk of having another heart attack.